Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | CNR2 | P34972 | 3/20 | 0.76 |
| ▸ | FAAH | O00519 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228084 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL17111171 | 0.95 | CNR1 (0.90) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL14239652 | 0.92 | CNR1 (0.85) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL12319236 | 0.91 | CNR1 (0.83) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL13518459 | 0.90 | CNR1 (0.82) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL8052707 | 0.90 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL1228841 | 0.90 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL13767988 | 0.90 | CNR1 (1.00) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL13518460 | 0.90 | CNR1 (0.82) | CNR1ALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL29989035 | 0.90 | CNR1 (0.81) | CNR1ALDH1A1CNR2FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2521447-B1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9562210-B1 | Methods for production of fatty acid alkanolamides (FAAAs) from microalgae biomass | THE UNIVERSITY OF TOLEDO (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| US-8420602-B2 | May be coupled with endorphin, enkephalin, dynorphin or endomorphin; for traversing blood brain barrier | MILLER LANDON C G (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420602-B2 | May be coupled with endorphin, enkephalin, dynorphin or endomorphin; for traversing blood brain barrier | MILLER LANDON C G (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-2521447-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011085211-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065909-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885ALDH1A1 972/4885CNR2 2347/4885 |
| US-20110172240-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885ALDH1A1 972/4885CNR2 2347/4885 |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | ORAI1, RYR2, CASR | CNR1 55/4885ALDH1A1 2643/4885CNR2 72/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | CNR1 2881/4885ALDH1A1 3440/4885CNR2 2509/4885 |
| US-20160340294-A1 | FATTY ACID FUMARATE DERIVATIVES AND THEIR USES | FH, FASN, ELOVL1 | CNR1 3320/4885ALDH1A1 972/4885CNR2 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.